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China, and Graz, AustriaBackground: IL-17A is a key driver of human autoimmune
diseases, particularly psoriasis.
Objective: We sought to determine the role of IL-17A in
psoriasis pathogenesis and to identify a robust and measurable
biomarker of IL-17A–driven pathology.
Methods: We studied 8 healthy subjects and 8 patients with
psoriasis before and after administration of secukinumab, a
fully human anti–IL-17A mAb, and used a combination of
classical techniques and a novel skin microperfusion assay to
evaluate the expression of 170 proteins in blood, nonlesional
skin, and lesional skin. For validation, we also tested stored sera
from 601 patients with a variety of autoimmune diseases.
Results: IL-17A was specifically expressed in lesional compared
with nonlesional psoriatic skin (9.8 vs 0.8 pg/mL, P < .001).
Proteomic and gene transcription analyses revealed
dysregulated antimicrobial peptides, proinflammatory
cytokines, and neutrophil chemoattractants, levels of which
returned to normal after treatment with secukinumab.
b-Defensin 2 (BD-2) was identified as a biomarker of IL-
17A–driven pathology by comparing protein expression in
patients with psoriasis versus that in healthy subjects (5746 vs
82 pg/mL in serum, P < .0001; 2747 vs <218 pg/mL in dermis,
P < .001), responsiveness to secukinumab therapy, and
synergistic induction by IL-17A and TNF-a in epidermal
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http://dx.doi.org/10.1016/j.jaci.2016.06.038autoimmune diseases thought to be IL-17A driven, we found
that BD-2 levels are most highly increased in patients with
psoriatic skin lesions, and in patients with psoriasis, BD-2 levels
correlated well with IL-17A levels (r 5 0.70, n 5 199, P < .001)
and Psoriasis Area and Severity Index scores (r 5 0.53, n 5 281,
P < .001).
Conclusion: IL-17A is a primary driver of skin pathology in
patients with psoriasis, and serum BD-2 is an easily measurable
biomarker of IL-17A–driven skin pathology. (J Allergy Clin
Immunol 2016;nnn:nnn-nnn.)
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TH17 cells and the IL-17 family of cytokines are key
drivers of autoimmune diseases, such as psoriasis, psoriatic
arthritis (PsA), ankylosing spondylitis (AS), rheumatoid
arthritis (RA), and multiple sclerosis (MS).1 Psoriasis is the
best studied of these diseases, with multiple interventions
targeted at TH17 cells and their cytokines showing efficacy in
its treatment.
The IL-17 family of cytokines includes 6 members (IL-17A to
IL-17F) that function as homodimers or heterodimers to
signal through a family of cytokine receptors with multiple
chains (IL-17RA to IL-17RE), with IL-17A and IL-17F signaling
through a receptor complex composed of IL-17RA and
IL-17RC.2,3 Circulating levels of IL-17A protein have been
shown to be higher in patients with psoriasis than in healthy
control subjects and correlate with disease severity,4 whereas
mRNA expression of the IL17A, IL17C, and IL17F genes is
higher in psoriatic lesional tissue than nonlesional tissue.5-7
Indeed, therapies that target either IL-17A or IL-17RA are
similarly highly effective in reducing disease in patients with
psoriasis.1,8-11 Although these numerous lines of evidence
implicate an important role for IL-17A, a nonredundant role for
IL-17F has not been precluded.
Much of our current understanding of psoriasis pathophysi-
ology and the effects of IL-17A blockade has largely been
based on studies evaluating gene expression from skin
biopsy specimens.6,12-14 Although these studies have provided
significant insights into the pathways that might be involved in
IL-17A–mediated pathogenesis, they are limited by the frequent
incongruence between changes in mRNA and protein expression.
Furthermore, they do not quantify the early microanatomically1
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such as cytokines and chemokines. To date, protein expression
response to therapy in psoriatic skin has been mostly demon-
strated on a qualitative rather than quantitative level through the
use of histology and immunohistochemistry (IHC).12,14-16
To increase our understanding of the inflammatory pathophys-
iology in psoriatic skin at a protein expression level and to
identify a protein biomarker of IL-17A–mediated pathology, we
conducted an exploratory study in 8 healthy subjects and 8
patients with psoriasis to quantify and compare the soluble
proteomic profiles of lesional versus nonlesional skin before
and after single-dose systemic treatment (300 mg administered
subcutaneously) with secukinumab (a fully human anti–IL-17A
mAb with a half-life of approximately 27 days) and/or healthy
skin. Dermal open flow microperfusion, a novel technique that
provides minimally invasive access to dermal interstitial fluid
(dISF), was used to sample the dermis.17-19 Dermal (dISF) sam-
ples were then analyzed for 170 proteins encompassing cytokines,
chemokines, growth factors, cell adhesion molecules, and soluble
receptors. Early proteomic changes that occur within the dermis
after secukinumab treatment were complemented with gene
expression changes extracted from full skin biopsy specimens.
Our aim was to identify which pathways might be central to
psoriasis pathology in skin and whether the antimicrobial peptide
b-defensin 2 (BD-2) might be a protein biomarker of IL-17A–
mediated pathology.METHODS
Study design
This single-center clinical study was conducted according to ethical
principles and good clinical practice at the Medizinische Universit€at in
Graz, Austria, after being approved by the ethics committee and Austrian
health authority. Enrolled patients needed to sign informed consent forms and
comply with the protocol requirements (ClinicalTrials.gov Identifier
NCT01539213).
We enrolled 8 healthy subjects (mean age, 26.1 years) and 8 patients with
psoriasis (mean age, 38.8 years). All 16 subjects were white, and all patients
with psoriasis were male, as were 6 healthy subjects. All subjects received a
single 300-mg subcutaneous injection of secukinumab on study day 1. Skin
biopsy specimens (4-mm skin punch), serum samples, and dermal samples
were obtained on study days 1 (before secukinumab treatment), 8 and 15 (7
and 14 days after secukinumab treatment). Details of the dermal sampling
methodology were described previously.19In addition, baseline serum from patients with various inflammatory
diseases sampled in multicenter trials conducted after ethics committee and
health authority approval have been analyzed. Sera analyzed were from 289
patients with psoriasis (NCT01539213 and NCT00941031), 37 patients with
PsA (NCT00809614), 56 patients with AS (NCT00809159), 68 patients with
MS (NCT01051817), 94 patients with RA (NCT01426789), and 57 patients
with Crohn disease (CD; NCT00584740).
Protein and RNA measurements
Free IL-17A and IL-17F levels in serum and dISF were quantified by using
microparticle-based fluorescent sandwich immunoassays based on Erenna
technology validated in human serum (Singulex IL-17A Human Immuno-
assayKit, catalog no. 03-0017-05; Singulex IL-17FHuman ImmunoassayKit,
catalog no. 03-0018-03; Singulex, Alameda, Calif). The lower limit of
quantification (LLOQ) for IL-17A was 0.64 pg/mL in dISF and 0.096 pg/
mL in serum, and that for IL-17F was 96.6 pg/mL in dISF and 14.4 pg/mL in
serum. BD-2 was quantified by using ELISA (Alpha Diagnostic, catalog no.
100-250-BD-2). The LLOQ for BD-2 was 218 pg/mL in dISF and 32.5 pg/mL
in serum. Sinistrin served as a reference substance andwas used to estimate the
absolute concentrations of biomarkers in dISF.19
The chemiluminescent multiplex enzyme immunoassay platform from
Aushon BioSystems (Billerica, Mass) was used to profile and quantify the
levels of 170 proteins distributed over 43 panels. The panel of 170 proteins
encompasses cytokines, cytokines receptor, chemokines, cell adhesion
molecules, angiogenesis factors, matrix metalloproteinases (MMPs), growth
factors, and neurotrophic factors (see Table E1 in this article’s Online Repos-
itory at www.jacionline.org).
Total RNAwas isolated from skin biopsy specimens by using the Qiagen
RNeasy Micro Kit (Qiagen, Hilden, Germany). RNA isolated from commer-
cial skin biopsy specimens (Asterand UK, Royston, United Kingdom) from
healthy subjects (n 5 10) served as controls for gene expression data. Gene
expression analysis was done by using quantitative RT-PCR (qRT-PCR) or
NanoString technology (NanoString Technologies, Seattle, Wash). See the
Methods section and Table E2 in this article’s Online Repository at www.
jacionline.org for further details.
Cell culture
Human primary skin cells were obtained from PromoCell (Heidelberg,
Germany). Epidermal keratinocytes (adult, pooled donors, passage 5, 30,300
cells/cm2), dermal fibroblasts (adult, single donor, passage 6, 30,300 cells/cm2),
and dermal microvascular endothelial cells (juvenile, pooled donors, passage 5,
22,700 cells/cm2) were seeded onto 96-well plates and incubated overnight.
Thereafter, cells were incubated for another 20 hours in medium alone or
0.03 to 960 ng/mL IL-17A in the absence or presence of 1 ng/mL TNF-a,
0.03 to 960 ng/mL IL-17F in the absence or presence of 1 ng/mL TNF-a, or
0.03 to 960 ng/mLTNF-a. Supernatants were examined for the release of BD-2.Statistical analysis
For the skin microperfusion study, log-transformed baseline (day 1) IL-
17A and IL-17F protein levels were analyzed by using a mixed effects model
with site (healthy volunteer or patient for serum levels and lesional or
nonlesional psoriatic skin for skin levels) as a fixed effect and subject as a
random effect, respectively. The adjusted geometric means (GMs) at each site
were provided on the original scale together with the P values for comparisons
between sites. Pearson correlation coefficients (denoted by r) between base-
line protein levels (IL-17A and IL-17F) and efficacy scores (Psoriasis Area
and Severity Index [PASI] score) were calculated together with the corre-
sponding P values by site. Log-transformed baseline BD-2 levels in serum
and skin were also analyzed by using a mixed effects model with site (healthy
volunteer or patient for serum levels and healthy and lesional or nonlesional
psoriatic skin for skin levels) and subject as a random effect, respectively.
The adjusted GMs at each site were provided on the original scale together
with the P values for comparisons between sites. IL-17F levels in serum
from patients with psoriasis and BD-2 levels over time in serum and skin
were log-transformed and analyzed by site by using a mixed effects model
FIG 1. Baseline dermal protein levels of IL-17A are significantly increased in lesional versus nonlesional
psoriatic skin and correlate with disease activity (PASI). A and B, Correlation plots of PASI scores versus IL-
17A levels (Fig 1, A) and PASI scores versus IL-17F levels (Fig 1, B). A linear regression fit is depicted by a red
line, the strength of the linear relationship is indicated by using the Pearson correlation coefficient r, n in-
dicates the number of values on each plot, and the P value shows the probability that the slope of the
true relationship is zero. C, Baseline IL-17A and IL-17F levels in the dermis (dISF) of healthy volunteers
(HV, circles) and lesional (L, squares) and nonlesional (NL, triangles) skin from patients with psoriasis.
Red lines and values represent the adjusted GMs and are adjusted for relative recovery of the reference sub-
stance sinistrin (Dragatin et al19). Data less than the LLOQ were imputed as half LLOQ and are shown as
open symbols. **P < .01. NS, Not significant (P > .05); NT, not testable because of the number of samples
less than the LLOQ in both groups.
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random effect, respectively. The adjusted GMs and 95% CIs at each visit
were provided on the original scale together withP values for comparisons be-
tweenvisits. Pearson correlation coefficients betweenBD-2 levels and efficacy
(PASI) scores were calculated together with the correspondingP values by site
and visit. Any values less than the LLOQ (note: values less than the LLOQ
differ for some samples because of a different sample dilution factor applied)
were imputed by half the LLOQ.
In the secukinumab dose regimen study in patients withmoderate-to-severe
psoriasis (NCT00941031), serum samples were taken and analyzed for BD-2,
IL-17A, and IL-17F. Correlations between PASI scores and BD-2, IL-17A,
and IL-17F levels were investigated by using a Pearson correlation coefficient.
BD-2, IL-17A, and IL-17F values were log-transformed before analysis.
Values of less than the LLOQ were not included in the calculations.
Analyses were performed with PROC MIXED and PROC CORR in SAS
software, version 9.4 (SAS Institute, Cary, NC).
RESULTS
Baseline IL-17A protein levels are increased in
lesional versus nonlesional skin of patients with
psoriasis
To understand the relative roles of IL-17A and IL-17F in
psoriasis, we evaluated protein levels in the circulation (serum)and skin (dISF) of the 16 subjects in our study (NCT01539213).
Consistent with previous studies, baseline serum IL-17A protein
levels were higher in patients with psoriasis than in healthy sub-
jects (GM: 0.5 vs 0.2 pg/mL, respectively; P <.05). Posttreatment
serum levels of free IL-17A could not be assessed because the IL-
17A assay used measures not only free IL-17A but also IL-17A
bound to secukinumab. No validated assay exists to measure
free IL-17A in the presence of secukinumab. Serum IL-17F levels
in patients with psoriasis (17.5 pg/mL) did not change signifi-
cantly at day 15 from baseline after secukinumab (14.9 pg/mL,
P 5 not significant). At baseline, serum IL-17A protein levels
correlated well with PASI scores (r 5 0.93, P < .001; Fig 1, A),
whereas baseline IL-17F levels did not (r 5 0.01, P 5 .98;
Fig 1, B).
Dermal (dISF) levels of IL-17A protein at baseline were
significantly higher in lesional than nonlesional psoriatic skin
(GM: 9.8 vs 0.8 pg/mL, respectively; P < .01; Fig 1, C). IL-17A
was not detectable in the normal skin of healthy subjects (less
than the LLOQ: <0.64 pg/mL). In contrast, baseline IL-17F levels
in dISF were not significantly different between lesional and non-
lesional skin, although IL-17F levels tended to be higher in le-
sional than nonlesional skin (GM: 317 vs 163 pg/mL,
FIG 2. Proteomic analysis of dermis (dISF) and serum from patients with psoriasis after IL-17A blockade
reveals early molecular changes and identifies BD-2 as a potential IL-17A response biomarker. Heat map of
89 proteinswith at least a 1.5-fold change (FC) at either day 8 or day 15 compared with baseline in the dermis
(dISF) or circulation (serum) of patients with psoriasis treated at day 1 with secukinumab. Dermal samples
were taken from lesional skin. Hierarchical clustering was performed on the protein concentration data to
show patterns of expression of related proteins in different compartments at 2 time points. Blue represents
downregulation from baseline, and red indicates upregulation.
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measurable in the normal skin of healthy subjects (less than the
LLOQ of 96.6 pg/mL; Fig 1, C). Transcriptional analysis of IL-
17 family members (IL-17A to IL-17F) in skin biopsy specimens
confirmed these findings by demonstrating upregulation of
mRNAs for IL-17A, IL-17F, IL-17C, and potentially IL-17E
(IL-25) in psoriatic lesional skin compared with healthy skin,
whereas expression of IL-17B was unchanged and that of IL-
17D was reduced (see Fig E1 in this article’s Online Repository
at www.jacionline.org). Consistent with changes in protein levels,
IL17A and IL17F mRNA levels were reduced after secukinumab
treatment (see Fig E1).Proteomics screening of serum and dISF for IL-17A–
responsive markers
To identify potential markers of IL-17A response proteins, we
used a hypothesis-free proteomics screening approach measuring
170 proteins in dISF and serum before and after secukinumab
treatment. By using a 1.5-fold change from baseline as a
threshold, 89 proteins were shown to be dysregulated in dISF,
serum, or both after treatment with secukinumab (Fig 2). The 10
proteins showing the greatest fold decrease were antimicrobial
peptides (BD-2 and lipocalin-2 [NGAL or LCN2]), MMPs
(MMP-1 and MMP-8), IL-1 pathway members (IL-1b and
IL-1ra), neutrophil proteins (myeloperoxidase), and neutrophil-
attracting (growth-regulated alpha protein [GRO-a] or CXCL1
and epithelial cell–derived neutrophil-activating peptide 78
[ENA-78] or CXCL5) or TH17 cell–attracting (macrophage
inflammatory protein 3a or CCL20) chemokines (Table I). Levels
of other chemokines, including GRO-g/CXCL3 and I-309/CCL1,
were also decreased after secukinumab. We could not detect a
change in TNF-a levels. The 5 proteins showing the greatest
fold increase were TH2 cell–associated proteins (IgE and
eotaxin-2/CCL24), adiponectin (Acrp-30), leptin, and endoglin.An early downregulation of the antimicrobial peptides BD-2 (en-
coded by the gene DEFB4A), BD-3 (DEFB103B), lipocalin-2
(LCN2), LL-37 (CAMP), S100A8, and S100A9, as well as neutro-
phil- and TH17-attracting chemokines (CXCL1, IL-8/CXCL8, and
CCL20, respectively) and the IL-1 family members IL-36a
(IL36A), IL-36b (IL36B), IL-36g (IL36G), and IL-36RN
(IL36RN), was also observed on the mRNA level (see Figs E2-
E4 in this article’s Online Repository at www.jacionline.org),
thereby confirming and extending observations made on the
protein level. BD-2 (also known as skin antimicrobial peptide
1) was the protein showing the highest fold change in both dermis
and serum and was selected for further study.BD-2 levels correlate with IL-17A and psoriasis
clinical severity and decrease after IL-17A blockade
BD-2 levels were further and more specifically quantified by
usingELISA in skin (dISF) and serumbefore and after secukinumab
treatment (Fig 3). At baseline, serum levels of BD-2 protein were
significantlyhigher in patientswith psoriasis than inhealthy subjects
(GM: 5746 vs 82 pg/mL, respectively;P <.001; Fig 3). SerumBD-2
levels decreased rapidly in patients with psoriasis after a single
300-mg subcutaneous dose of secukinumab (GM: 971 pg/mL at
day 8 and 649 pg/mL at day 15; P < .0001 vs baseline for both
time points). Dermal (dISF) BD-2 levels were also significantly
higher in lesional skin than in nonlesional psoriatic skin at baseline
(GM: 2747 vs 417 pg/mL, respectively,P <.001; Fig 3). In contrast,
dermal BD-2 levels in healthy subjects were all less than the LLOQ
(P <.001 vs lesional skin in patients with psoriasis, Fig 3). After se-
cukinumab treatment, mean BD-2 levels in lesional skin decreased
by 80% at day 8 and approached levels close to the LLOQ at day
15 after treatment with secukinumab (GM: 550 pg/mL at day 8
[P < .05] and 196 pg/mL at day 15 [P < .01], Fig 3). Thus BD-2 in
both serum and dISF is responsive to IL-17A inhibition.
TABLE I. Proteins with the greatest fold change and selected proteins of interest in skin (dermis) or circulation (serum) of patients
with psoriasis after treatment with a single dose of the IL-17A inhibitor secukinumab
Protein
Fold change relative to baseline
Dermis (dISF) Serum
Day 8 Day 15 Day 8 Day 15
Top 10 downregulated
BD-2 218.73 232.20 23.95 23.66
MMP-1 26.20 215.19 21.11 1.04
IL-1b 22.71 25.47 1.14 1.14
IL-1 receptor antagonist (IL-1ra) 22.19 24.37 21.47 22.32
MMP-8 21.91 23.42 21.16 21.07
Myeloperoxidase 21.18 23.20 21.27 21.18
CXCL1 (GRO-a, CXCL1) 22.63 23.13 21.08 21.17
Lipocalin-2 (NGAL, LCN2) 22.14 22.98 21.11 21.12
CCL20 (Macrophage inflammatory protein 3a, CCL20) 22.62 22.64 21.24 1.45
CXCL5 (ENA-78, CXCL5) 23.00 22.50 1.05 21.02
Other proteins of interest
CXCL3 (GRO-g, CXCL3) 21.61 22.20 21.16 21.08
CCL1 (I-309, CCL1) 21.34 21.88 1.09 1.03
TNF-a 1.00 1.18 1.04 1.03
Top 5 upregulated
Endoglin 2.51 2.52 1.04 1.08
Leptin 2.59 2.62 1.09 1.39
Adiponectin (Acrp-30) 1.50 2.72 1.13 21.04
Eotaxin-2 (CCL24) 1.56 2.77 1.06 1.14
IgE 1.92 3.19 21.00 21.06
FIG 3. BD-2 protein levels are increased in patients with psoriasis and rapidly decrease in dermis and serum
after secukinumab treatment. Upper panel, left, Baseline human BD-2 levels in the serum of healthy volun-
teers (HV) and patients with psoriasis (Pso). Upper panel, right, Serum BD-2 levels after a single dose of
300 mg of secukinumab administered subcutaneously (GM 6 95% CI). Lower panel, left, Baseline BD-2
levels in the dermis (dISF) of lesional (Pso L) and nonlesional (Pso NL) skin from patients with psoriasis
and skin from healthy subjects (HV). Lower panel, right, Dermal BD-2 levels after a single dose of 300 mg
of secukinumab administered subcutaneously (GM 6 95% CI). Red horizontal bars depicts the GM concen-
tration. All data less than the LLOQ (218 pg/mL for healthy volunteers and 109 pg/mL for patients with pso-
riasis) were imputed as half LLOQ and are shown as open symbols. **P < .01 and ***P < .001.
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we tested cytokine-stimulated BD-2 expression in epidermal
keratinocytes, dermal fibroblasts, and dermal microvascularendothelial cells. Of the 3 cell types, only epidermal keratino-
cytes produced BD-2 (Fig 4). Although IL-17A, IL-17F, and
TNF-a all induced low levels of BD-2 at high concentrations,
FIG 4. BD-2 expression by different primary human skin cell types. Levels of BD-2 (means 6 SDs, n 5 3) in
supernatants of either epidermal keratinocytes, dermal fibroblasts, or dermal microvascular endothelial
cells stimulatedwith different concentrations of human IL-17A, IL-17F, or TNF-a alone or IL-17A and IL-17F in
combination with a low concentration of TNF-a.
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induced high levels of BD-2 expression. Thus epidermal kerati-
nocytes are the IL-17A–responsive skin cell type for BD-2
production.
To determine whether BD-2 could be a marker of psoriasis
disease activity, we compared BD-2 serum levels with PASI
scores. The clinical efficacy of secukinumab has been previously
documented, and similarly in this study, the mean PASI score
decreased by 62.5% at day 22 after a single dose of 300 mg of
secukinumab administered subcutaneously (P < .0001 vs base-
line). BD-2 levels also decreased in correlation with reductions
in clinical disease severity (PASI scores at baseline, day 8, and
day 15; r 5 0.87-0.89; P < .01). These data were confirmed by
analyzing stored baseline serum samples from a second, larger
phase 2b study in patients with psoriasis (NCT00941031).20 In
this validation cohort there was a significant correlation between
serum BD-2 and IL-17A levels (n 5 199; r 5 0.70, P < .001,
Fig 5), as well as serum BD-2 levels and PASI disease activity
(n 5 281, r 5 0.53, P < .001; Fig 5). Thus serum BD-2 levels
correlate with both serum IL-17A levels and psoriasis disease ac-
tivity. Furthermore and in line with the close correlation of serum
levels of BD-2 with IL-17A, serum levels of IL-17A show a sig-
nificant correlation with psoriasis disease activity (n 5 206,
r 5 0.44, P < .001; Fig 5). Little correlation was observed for
IL-17F with either psoriasis disease activity (n 5 177,
r 5 0.15, P < .05; Fig 5) or serum BD-2 levels (n 5 173,
r 5 0.15, P < .05; Fig 5).Because IL-17A levels are increased and IL-17A is a
pathogenic driver in multiple autoimmune diseases, we sought
to determine whether BD-2 could be a marker of IL-17A activity
in patients with diseases other than psoriasis. We analyzed BD-2
levels in stored baseline serum (n 5 601) from previous clinical
studies in several autoimmune diseases. BD-2 levels were highly
increased in the sera of patients with diseases having skin
involvement, such as psoriasis and PsA, and only at moderate
levels in thosewith diseases with minimal to no skin involvement,
such as AS, RA, MS, and CD (Fig 6). Although previous or cur-
rent psoriatic inflammation of the skin is required for the diag-
nosis of PsA, many patients with PsA do not have detectable
skin lesions at the time of evaluation. Thus we evaluated whether
BD-2 levels were different in subjects with or without ongoing
skin involvement and found that BD-2 levels were higher in those
patients with active skin involvement compared with those who
did not (GM: 1493 vs 454 pg/mL, P < .01). We also assessed
IL-17A and IL-17F levels in patients with psoriasis, PsA, and
AS and found that they were expressed at similar levels in PsA pa-
tients with or without skin involvement (Fig 6). Thus BD-2 ap-
pears to be a biomarker of IL-17A pathogenesis in the skin.DISCUSSION
In this study our aims were to (1) better understand the role of
IL-17A in psoriasis pathogenesis by defining the early effects of
IL-17A blockade on inflammatory proteins in both serum and the
FIG 5. Baseline serum BD-2 levels correlate with IL-17A levels and disease activity (PASI scores). Correlation
plots of PASI scores and protein levels from stored samples from the AIN457 Regimen Finding Study in
Patients withModerate to Severe Psoriasis (ClinicalTrials.gov identifier: NCT00941031).Upper panel, IL-17A
level versus BD-2 level. Middle panel, left, PASI score versus BD-2 level. Middle panel, right, IL-17F level
versus BD-2 level. Lower panel, left, PASI score versus IL-17A level. Lower panel, right, PASI score versus
IL-17F level. In each plot the red line is from a linear regression fit, the strength of the linear relationship
is indicated by using the Pearson correlation coefficient r, and n indicates the number of values on each
plot. The P value is from a test that the slope of each linear regression line equal zero; the smaller the P
value, the less likely it is that the slope of the true relationship equals zero.
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activation.
Previous studies quantifying skin gene expression by using
transcriptomics or qualitatively assessing protein expression by
means of IHC before and after anti–IL-17A therapy have
provided important information,12,13 but the conclusions are
limited by the often discrepant timing and levels of gene and
protein expression. This might be of particular relevance
because proteins are the final effector molecules in biological
systems and significant differences to their corresponding
mRNA levels can exist.21 To quantify soluble skin proteins
involved in psoriasis pathogenesis, we used dermal open flow
microperfusion.18As predicted based on IHC and mRNA transcription data, we
found high IL-17A protein levels in lesional skin from patients
with psoriasis. Similarly and consistent with previous12,13 and our
own mRNA transcription data, we could not detect either IL-17A
or IL-17F protein in skin of healthy volunteers. Interestingly, we
found detectable but lower IL-17A protein levels in nonlesional
skin of patients with psoriasis (2/8 tested), suggesting that nonle-
sional skin is not normal and has a low level of ongoing IL-17A
pathway activation. In the serum we confirmed previous data,
now using a highly sensitive and validated assay, that IL-17A
levels in our small study of 8 subjects are increased in patients
with psoriasis and correlate with disease activity. Although IL-
17F protein levels in patients with psoriasis were much higher
FIG 6. Baseline BD-2, IL-17A, and IL-17F serum levels in patients with autoimmune diseases (log scale).
Distribution of BD-2, IL-17A, and IL-17F baseline levels across indications from 6 different clinical studies.
PsA1 indicates data from patients with skin psoriasis and PsA- indicates data from patients without any skin
involvement. The number in parentheses denotes the number of samples tested. The red line indicates the
location of each GM value, and its value is indicated by red text.
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sional versus nonlesional skin in all psoriasis plaques and did not
correlate with psoriasis disease activity as measured by using
PASI scores. One possible explanation for this discrepancy is
that IL-17A is about 100-fold more potent than IL-17F for
signaling through IL-17R,22 a feature also seen for BD-2 induc-
tion in keratinocytes in Fig 4. We sought to validate this finding
using a larger independent cohort of patients with psoriasis. In
the validation set serum IL-17A levels continued to have a good
correlation, whereas IL-17F levels had a weaker if not poor cor-
relation with PASI scores. Combined with the excellent and
similar efficacy of compounds that target IL-17RA (which blocks
IL-17A, IL-17C, IL-17E, and IL-17F) and IL-17A only (reviewed
in Patel and Kuchroo1), we conclude that IL-17A has a more
dominant role in driving pathologic changes in psoriatic skin
than IL-17F.
To identify in vivo IL-17A–responsive proteins, we treated pa-
tients with psoriasis with a single dose of secukinumab, a selec-
tive anti–IL-17A antibody with previously demonstrated11,12,23
pharmacology and clinical efficacy in patients with psoriasis. Se-
cukinumab has been shown in the patients evaluated in this study
to reach pharmacologically active skin concentrations at the time
of sampling.19 Proteomics analysis after selective blockade with
secukinumab showed that most changes occurred in the dermis.
Many of the most strongly downmodulated proteins mapped tothe canonical IL-17A pathway (MetaCore from Thomson
Reuters) and were linked to keratinocyte activation, inflamma-
tion, and neutrophil and leukocyte/dendritic cell recruitment.24
Three of the 10 top downregulated proteins (myeloperoxidase,
CXCL1, and CXCL5) were neutrophil associated, verifying
previously described effects of anti–IL-17A therapy on this
hallmark feature of psoriasis25 and the established role of
IL-17A in inducing neutrophil recruitment. As previously seen
with transcriptional analysis, the protein expression of IL-1b,
MMP-1, and MMP-8 in skin decreased after IL-17A blockade.
However, the changes were limited to the skin and not seen in
serum, likely because of the restricted local production and action
of IL-1b andMMPs. Similarly, the chemokines CXCL1, CXCL3,
CXCL5, CCL1, and CCL20 were also decreased in the skin but
not serum after secukinumab, destroying the chemokine gradient
from serum into skin. Although TNF-a mRNA expression is
decreased after secukinumab,12 we did not detect changes in
protein levels in this study. The 2 proteins with levels that
increased most in dISF were IgE and CCL24, suggesting a
skewing of the skin immune response from TH17 to TH2.
Interestingly, mRNA for IL-17E (IL-25), which promotes TH2,
was also slightly increased in skin after secukinumab
therapy. Thus IL-17A blockade leads to decreases in skin
proinflammatory cytokines, decreased destruction of the
connective tissues, skewing of the immune response away from
J ALLERGY CLIN IMMUNOL
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neutrophils, into the skin.
BD-2 was the protein with by far the biggest change in the
dermis and serum after anti–IL-17A treatment (Fig 2 and Table I).
This confirms on a protein level the finding that levels ofDEFB4A
mRNA encoding BD-2 protein are decreased after IL-17A
blockade.12,13 DEFB4A mRNA is highly induced by IL-17A
in epidermal keratinocytes and reconstituted human
epidermis,13,26-28 and BD-2 protein is primarily located in the
epidermal layer of the skin,29,30 where it is a potent antimicrobial
peptide.31 In addition, BD-2 is chemotactic for cells that express
CCR2,32 CCR6,33 or both, such as neutrophils,32,34 monocytes/
macrophages,32 immature dendritic cells, and T cells,35 and is
involved in arrest of TH17 cells on inflamed endothelium.
27 Our
study confirms BD-2 is expressed in skin by epidermal keratino-
cytes, and recent results show that its expression is highly induced
by IL-17A in a synergistic manner with TNF-a.36 Thus BD-2 is an
IL-17A–responsive innate inflammatory protein produced in the
skin by epidermal keratinocytes.
With the above information, we sought to definewhether BD-2
could be validated as a biomarker of IL-17A–mediated skin
pathology in patients with psoriasis. We also recognized that a
serum biomarker would be more useful than one that would
require a skin biopsy or microperfusion. Previously, Jansen et al29
showed that serum BD-2 levels correlated with psoriasis disease
severity, as defined by PASI score.We have confirmed this finding
with a larger cohort of patients with psoriasis and have extended it
by showing that serum BD-2 levels correlate even more strongly
with IL-17A. Importantly, neutralizing IL-17Awith secukinumab
decreased BD-2 levels not only in skin but also in serum, and this
reduction occurred within 1 week, the earliest time point that we
measured. Given the dramatic reduction seen at 1 week after se-
cukinumab treatment, it is likely that BD-2 responds even earlier.
Lastly, we tested BD-2 levels in baseline serum samples from pa-
tients with diseases thought to be IL-17A driven and showed that
BD-2 levels were most highly increased in patients with psoriatic
skin inflammation.
However, there are caveats and limitations of this study. First,
many of the mechanistic findings in the dermis were made in a
relatively small number of subjects. However, we could confirm a
link between the dermis and serum in our cohort and then
reproduce many findings in serum from a larger cohort. Larger
studies with skin microdialysis would be needed to confirm the
dermal rather than serum data. By using IHC, other candidates for
soluble biomarkers of IL-17A activity in patients with psoriasis
have emerged, including S100A7 and S100A8,13 but these pro-
teins were not evaluated here. BD-2 might also respond to medi-
ators other than IL-17A, and our study shows that IL-17A acts in
synergy with TNF-a to induce BD-2 by skin epithelium. There
are conflicting data regarding the effect of TNF-a blockade or
other effective psoriasis treatments on BD-2 levels. In one study
DEFB4A mRNA levels in skin biopsy specimens did not change
after etanercept, whereas they did decrease dramatically with
IL-17A blockade.13 In another study BD-2 protein staining was
qualitatively decreased by IHC after etanercept.15 There was no
decrease, and possibly an increase, in serum BD-2 levels after
treatment with fumaric acid esters.37 Increased serumBD-2 levels
have been linked to atopic dermatitis and systemic lupus
erythematosus,38-40 and BD-2 can be expressed by other epithelia
than skin, including lung and gastrointestinal epithelia.41,42
Although we did not detect high BD-2 levels in patients withgut inflammation (CD), we have not tested lung diseases. BD-2
is not an exclusive biomarker for IL-17A–mediated skin pathol-
ogy in psoriasis. However, all studies (including the current
one) testing the association of serum or skin BD-2 protein levels
and/or skinDEFB4AmRNA expression with psoriasis disease ac-
tivity, serum IL-17A levels, or response to IL-17A blockade are
consistent and robust.
In summary, our study shows that IL-17A is a dominant driver
of skin pathology in patients with psoriasis, and serum BD-2 is an
easily measurable biomarker of psoriasis disease activity that
responds rapidly and robustly to IL-17A inhibition by secukinu-
mab. Serum BD-2 levels might be a surrogate for IL-17A activity
and could be used to monitor responses to IL-17A–targeted
therapies.
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Clinical implications: Serum BD-2 might be a valuable
biomarker to predict and/or monitor response to IL-17A–based
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Gene expression analysis
Total RNA extraction. Four-millimeter punch skin biopsy tissue
samples were collected and immersed in 1.5 mL of RNAlater RNA Stabili-
zation Reagent. Total RNA was isolated from tissue samples by using the
Qiagen RNeasy Micro Kit and eluted in 12 mL of RNase-free water. RNA
isolated from commercial skin biopsy specimens (Asterand UK) from healthy
subjects (n5 10) served as controls for gene expression data. Twenty to 50 ng
of RNA was preamplified by using the Affymetrix SensationPlus FFPE
Amplification kit (Affymetrix, Santa Clara, Calif).
NanoString nCounter gene expression analysis. RNA
samples were processed with the nCounter Prep Station and Digital Analyzer
of NanoString Technologies. The custom-designed nCounter Gene Expres-
sion CodeSets C1933_Amadeus and C2018_Everest overall contained probe
sets for 314 target transcripts, 7 candidate reference genes for normalization,
and 2 sex control genes. Probe sequences for genes reported in this study are
shown in Table E2. Three hundred nanograms (C1933_Amadeus) or 25 ng
(C2018_Everest) of the preamplified sense RNA was hybridized with the
respective CodeSet at 658C for 16 hours.
Posthybridization processing procedures were carried out, as recommen-
ded by NanoString Technologies. Cartridges were scanned at a resolution of
600 fields of view. Gene expression barcode counts were analyzed with
nSolver Analysis software v1.1 (NanoString Technologies). Raw NanoString
barcode counts for each gene were subjected to an mRNA content-related
normalization by using the GMof the 3 reference genes (RPL13A,RPL19, and
UBC).
qRT-PCR gene expression analysis. qRT-PCR was applied
for expression analysis of IL-17 familymember genes. However, at the time of
qRT-PCR analysis, 2 individual RNA samples from 2 different subjects (one
from baseline and the other from day 8, which had the lowest total RNAyieldafter extraction) had already been exhausted by preceding microarray and
NanoString gene expression analyses. cDNA synthesis from mRNA was
performed with the iScript advanced cDNA synthesis kit (Bio-Rad Labora-
tories, Hercules, Calif) with 2000 ng of input of preamplified sense RNA
generated, as described above. Samples were processed with a cDNA (total
RNA equivalent) input of 10 ng per reaction (RPL13A, RPL19, and UBC) or
40 ng per reaction (IL17A, IL17B, IL17C, IL17D, IL17E, and IL17F) by using
predesigned probe-based qPCR assays from Integrated DNA Technologies
(Coralville, Iowa) or Life Technologies (Grand Island, NY; IL17A:
Hs.PT.56a.19213466; IL17B: Hs.PT.58.2931881; IL17C: Hs.PT.56a.
1093657; IL17D: Hs00370528_m1; IL25 [IL17E]: Hs03044841_m1;
IL17F: Hs.PT.56a.20717359; RPL13A: Hs.PT.56a.39648480.g; RPL19:
Hs.PT.56a.39989087; UBC: Hs.PT.39a.22214853). All samples were
measured in triplicate by using a QuantStudio 12K Flex instrument (Applied
Biosystems, Foster City, Calif). The real-time programwas 508C for 2minutes,
958C for 10 minutes (1 cycle), 958C for 15 seconds, and 608C for 60 seconds
(40 cycles). Automatic threshold settings were used. qRT-PCR results were
evaluated by using the QuantStudio 12k Flex software v1.1.1 (Applied Bio-
systems). For qRT-PCR, normalized relative quantities (RQs) were calculated
according to the method described by Hellemans et al.E1 The GM of the quan-
tification cycle values of all Asterand healthy skin reference samples was used
as a reference quantification cycle value for the calculation of RQs. RQ values
were then normalized by using the GM of the RQs of the 3 reference genes
RPL13A, RPL19, and UBC. According to the applied calculations, a normal-
ized RQ value of 1 reflects the GM of the respective gene expression in Aster-
and healthy skin reference samples.
FIG E1. Expression of IL-17 family member genes in skin biopsy specimens from patients with psoriasis and
healthy subjects before and after treatment with secukinumab. qRT-PCR was performed on skin biopsy
specimens from lesional skin of patients with psoriasis enrolled in the study (n5 6; data from 2 subjects are
not shown because of missing data at either baseline or day 8). Healthy control skin biopsy specimens
(n5 10) were obtained from a commercial source (Asterand). Y-axes show normalized RQs. Red lines depict
median values. *P < .05, **P < .01. NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers.
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FIG E2. Early transcriptional downregulation of b-defensins and antimicrobial peptides. mRNA gene
expression from lesional skin biopsy specimens and healthy subjects were all determined by using
NanoString technology. Healthy control skin biopsy specimens (n 5 10) were obtained from a commercial
source (Asterand). Y-axes show normalized RQs. Red lines depict median values. *P < .05, **P < .01.NS, Not
significant (P > .05). BL, Baseline; HV, healthy volunteers.
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FIG E3. mRNA expression analysis indicates early effects on TH17- and neutrophil-attracting chemokines.
mRNA gene expression from lesional skin biopsy specimens and healthy subjects were all determined
by using NanoString technology. Healthy control skin biopsy specimens (n 5 10) were obtained from a
commercial source (Asterand). Y-axes show normalized RQs. Red lines depict median values. *P < .05.
NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers.
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FIG E4. mRNA expression analysis indicates early effects of IL-17A blockade on the IL-1 family cytokines IL-
36a, IL-36b, and IL-36g. mRNA gene expression from lesional skin biopsy specimens and healthy subjects
was determined by using NanoString technology. Healthy control skin biopsy specimens (n 5 10) were
obtained from a commercial source (Asterand). Y-axes show normalized RQs. Red lines depict median
values. *P < .05, **P < .01. NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers.
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TABLE E1. Aushon protein analysis panel
Protein Entrez gene ID
a2-Macroglobulin 2
Acrp-30 (adiponectin) 9370
Ang-2 (angiopoietin 2) 285
Apo A-1 (apolipoprotein A-1) 335
Apo B-100 (apolipoprotein B-100) 338
AR (amphiregulin) 374
b-NGF (b nerve growth factor) 4803
sAPPb (soluble amyloid precursor protein b) 351
BCA-1/CXCL13 (B cell–attracting chemokine) 10563
BD-2 (b-defensin 2) 1673
BDNF (brain-derived neurotrophic factor) 627
BMP-9 (bone morphogenetic protein 9) 2658
Cathepsin D 1509
CC16 (Clara cell protein) 7356
CD14 (cluster of differentiation 14) 929
CD30/TNFRSF8 (cluster of differentiation 30) 943
CD40L (cluster of differentiation 40 ligand) 959
CGa (chorionic gonadotropin a) 1081
Clusterin 1191
CNTF (ciliary neurotrophic factor) 1270
COX-2 (cyclooxygenase 2) 5743
C-peptide 3630
CRP (C-reactive protein) 1401
E-cadherin 999
EGF (epidermal growth factor) 1950
EGFR (epidermal growth factor receptor) 1956
ENA-78 (epithelial cell–derived neutrophil-activating
peptide 78)
6374
Endoglin 2022
Eotaxin 6356
Eotaxin-2 6369
Eotaxin-3 10344
ER (epiregulin) 2069
ErbB2/Her2 (human epidermal growth factor receptor 2) 2064
E-selectin 6401
Exodus-2 (6Ckine) 6366
FasL (Fas ligand) 356
FGF basic (fibroblast growth factor basic) 2247
Fibrinogen 2243
Fibronectin 2335
G-CSF (granulocyte colony-stimulating factor) 1440
GDNF (glial cell–derived neurotrophic factor) 2668
GM-CSF (granulocyte macrophage colony-stimulating
factor)
1437
gp130 (glycoprotein 130) 3572
GROa (growth-regulated protein a) 2919
GROg (growth-regulated protein g) 2921
HCC-4/CCL-16 (hemofiltrate CC chemokine 4) 6360
HGF (hepatocyte growth factor) 3082
HGH (human growth hormone) 4261
I-309 6346
ICAM-1 (intercellular adhesion molecule 1) 3383
ICAM-3 (intercellular adhesion molecule 3) 3385
IFN-a (interferon a) 3440
IFN-g (interferon g) 3458
IgE (immunoglobulin E)
IGFBP-1 (insulin-like growth factor binding protein 1) 3484
IGFBP-2 (insulin-like growth factor binding protein 2) 3485
IGFBP-3 (insulin-like growth factor binding protein 3) 3486
IL-1a (interleukin 1 a) 3552
IL-1b (interleukin 1 b) 3553
IL-1ra (interleukin 1 receptor antagonist) 3557
(Continued)
TABLE E1. (Continued)
Protein Entrez gene ID
IL-1RI (interleukin 1 receptor I) 3554
IL-1RII (interleukin 1 receptor II) 7850
IL-2 (interleukin 2) 3558
IL-2Ra (interleukin 2 receptor a) 3559
IL-2Rg (interleukin 2 receptor g) 3561
IL-3 (interleukin 3) 3562
IL-4 (interleukin 4) 3565
IL-4R (interleukin 4 receptor) 3566
IL-5 (interleukin 5) 3567
IL-6 (interleukin 6) 3569
IL-6R (interleukin 6 receptor) 3570
IL-7 (interleukin 7) 3574
IL-8 (interleukin 8) 3576
IL-9 (interleukin 9) 3578
IL-10 (interleukin 10) 3586
IL-11 (interleukin 11) 3589
IL-12p40 (interleukin 12 p40 homodimer) 3593
IL-12p70 (interleukin 12 p70 heterodimer) 3592 and 3593
IL-13 (interleukin 13) 3596
IL-13Ra1 (interleukin 13 receptor a 1) 3597
IL-15 (interleukin 15) 3600
IL-16 (interleukin 16) 3603
IL-17A (interleukin 17A) 3605
IL-17E (interleukin 17E) 64806
IL-18 (interleukin 18) 3606
Insulin 3630
IP-10 (IFN-g–induced protein 10 kDa) 3627
I-TAC (interferon-inducible T-cell a chemoattractant) 6373
KGF (keratinocyte growth factor) 2252
Leptin 3952
LIF (leukemia inhibitory factor) 3976
L-selectin 6402
Lymphotactin 6375
MCP-1 (monocyte chemotactic protein 1) 6347
MCP-2 (monocyte chemotactic protein 2) 6355
MCP-3 (monocyte chemotactic protein 3) 6354
MCP-4 (monocyte chemotactic protein 4) 6357
MDC (macrophage-derived chemokine) 6367
MIF (migration inhibitory factor) 4282
MIG (monokine induced by IFN-g) 4283
MIP-1a (macrophage inflammatory protein 1 a) 6348
MIP-1b (macrophage inflammatory protein 1 b) 6351
MIP-1d (macrophage inflammatory protein 1 d) 6359
MIP-3a (macrophage inflammatory protein 3 a) 6364
MIP-3b (macrophage inflammatory protein 3 b) 6363
MIP-4/PARC (macrophage inflammatory protein 4,
pulmonary and activation-regulated chemokine)
6362
MMP-1 (matrix metalloproteinase 1) 4312
MMP-2 (matrix metalloproteinase 2) 4313
MMP-3 (matrix metalloproteinase 3) 4314
MMP-7 (matrix metalloproteinase 7) 4316
MMP-8 (matrix metalloproteinase 8) 4317
MMP-9 (matrix metalloproteinase 9) 4318
MMP-10 (matrix metalloproteinase 10) 4319
MMP-13 (matrix metalloproteinase 13) 4322
MPIF-1 (myeloid progenitor inhibitory factor 1) 6368
MPO (myeloperoxidase) 4353
NAP-2 (neutrophil activating peptide 2) 5473
NGAL (neutrophil gelatinase-associated lipocalin) 3934
NT3 (neurotrophin 3) 4908
NT-proBNP (N-terminal prohormone of brain natriuretic
peptide)
4879
(Continued)
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TABLE E1. (Continued)
Protein Entrez gene ID
OPG (osteoprotegrin) 4982
OPN (osteopontin) 6696
PAI-1 active (plasminogen activator inhibitor 1 active) 5054
PAI-1 total (plasminogen activator inhibitor 1 total) 5054
PAPP-A (pregnancy-associated plasma protein A) 5069
PD-1 (programmed death 1) 5133
PDGF-AA (platelet-derived growth factor AA) 5154
PDGF-AB (platelet-derived growth factor AB) 5154 and 5155
PDGF-BB (platelet-derived growth factor BB) 5155
PECAM-1 (platelet endothelial cell adhesion molecule) 5175
PEDF (pigment epithelium-derived factor) 5176
PLGF (placental growth factor) 5228
Prolactin 5617
Protein C 5624
P-selectin 6403
RAGE (receptor for advanced glycation end products) 177
RANK (receptor activator of NF-kB) 8792
RANKL (receptor activator of NF-kB ligand) 8600
RANTES (regulated upon activation, normal T cell
expressed and presumably secreted)
6352
RBP4 (retinol binding protein 4) 5950
Resistin 56729
SAA (serum amyloid A) 6288
SCF (stem cell factor) 4254
SDF-1 (stromal cell–derived factor 1) 6387
SHBG (sex hormone binding globulin) 6462
TARC (thymus and activation-regulated chemokine) 6361
TFF-3 (trefoil factor 3) 7033
TGF-a (transforming growth factor a) 7039
TGF-b1 (transforming growth factor b 1) 7040
TGF-b2 (transforming growth factor b 2) 7042
TM (thrombomodulin) 7056
TIM-1 (T cell immunoglobulin mucin 1) 26762
TIMP-1 (tissue inhibitor of metalloproteinases 1) 7076
TIMP-2 (tissue inhibitor of metalloproteinases 2) 7077
TNF-a active trimer (tumor necrosis factor a) 7124
TNF-a monomer 1 trimer (tumor necrosis factor a) 7124
TNF-RI (tumor necrosis factor a receptor I) 7132
TNF-RII (tumor necrosis factor a receptor II) 7133
TPO (thrombopoietin) 7066
TRAIL (TNF-related apoptosis-inducing ligand) 8743
TSLP (thymic stromal lymphopoietin) 85480
TSP-1 (thrombospondin-1) 7057
TSP-2 (thrombospondin-2) 7058
TWEAK (TNF-related and weak inducer of apoptosis) 8742
VCAM-1 (vascular cell adhesion molecule 1) 7412
VEGF (vascular endothelial growth factor) 7422
VEGF-C (vascular endothelial growth factor C) 7424
VEGF-D (vascular endothelial growth factor D) 2277
VEGF-R1 (vascular endothelial growth factor receptor 1) 2321
VEGF-R2 (vascular endothelial growth factor receptor 2) 3791
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TABLE E2. NanoString code set probe sequences for genes reported in this study
Gene identifier Capture probe sequence Reporter probe sequence
CAMP CTATAGCACGAAGCACAGCTTCCTTGTA
GCTGAGGACCTGGGCAATGATG
GTAGAGGTTAGCATCCGAGGACCGCTGGTTGATGCCAT
CCL20 CAGGAGCAAACTCTTGGTACAGCACATG
GTTTTTAGCTCAAAGAACAGAT
GCTTCTGATTCGCCGCAGAGGTGGAGTAGCAGCACTGACATCAAAGCAGC
CXCL1 CTCTATCACAGTGGCTGGCATGTTGCAGGC
TCCTCAGAAATATTAACATA
TTCACAATGATCTCATTGGCCATTTGCTTGGATCCGCCAGC
CXCL8 (IL8) CCGGTGGTTTCTTCCTGGCTCTTGTCCTAG
AAGCTTGTGTG
AGCCACGGCCAGCTTGGAAGTCATGTTTACACACAGTGAGATG GTTCCTT
DEFB4A TATGGCTCCACTCTTAAGGCAGGTAACAGG
ATCGCCTATACCA CCAAAAA
CCACAGGTGCCAATTTGTTTATACCTTCTAGGGCAAAAGACTGG ATGACA
DEFB103B TTTTTATTTCTTTCTTCGGCAGCATTTTCGGC
CACGCGTCGAGC ACTTG
CTTTAAGAAGGCATTTCCACACTTTACAACACTCTCGTCATGTTT CAGGG
LCN2 CTGATCCAGTAGTCACACTTCTTTTTCCTAA
ACAGGACGGAGGTGACATT
TAATGTTGCCCAGCGTGAACTCGCCGGGCTGGCAACCTGGAACAAAAGTC
RPL13A TCCTTGCTCCCAGCTTCCTATGTCCCAGGG
CTGCC
ATTCTCCGAGTGCTTTCAAGCAACTTCGGGAGGCAGTGACTAA GACCCTT
RPL19 AATCCTCATTCTCCTCATCCATGTGACCTTC
TCTGGCATTCGG GCATTGG
TGGCGATCGATCTTCTTAGATTCACGGTATCTTCTGAGCAGCC GGCGCAA
UBC CACTTCGAGAGTGATGGTCTTACCAGTCAGG
GTCTTCACGAAG ATCTGCA
TCCTTGTCTTGGATCTTTGCCTTGACATTCTCAATGGTGTCACT CGGCTC
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